Following a recent trial, doctors at the Christie Hospital are optimistic about the study of HMBD-001 in the treatment of bladder cancer.

Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel).

Novartis reported that its intrathecal (IT) formulation of onasemnogene abeparvovec (OAV101 IT) reached its primary endpoint in a Phase III study in paediatric patients aged two to 17 with type II ...

Hanx Biopharmaceuticals has dosed the first subject in a trial of HX044, a bispecific antibody designed for advanced solid tumours.

Cocrystal Pharma has announced its intent to extend enrolment for its Phase IIa human challenge trial of CC-42344 ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

According to GlobalData, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in post-surgery pain compared to placebo.

Sensorion has completed subject enrolment in the first cohort of Phase I/II Audiogene trial of gene therapy injection, SENS-501.

China NMPA's CDE has approved Alphamab Oncology’s IND for the multicentre Phase I/II JSKN033-102 trial of JSKN033.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142, a long-acting growth hormone.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.